Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Below 200 Day Moving Average – Here’s Why

Shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.91 and traded as low as $1.53. Aldeyra Therapeutics shares last traded at $1.55, with a volume of 471,861 shares.

More Aldeyra Therapeutics News

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: Several law firms, including Rosen, Faruqi & Faruqi, Schall, Pomerantz, and others, reiterated that investors who bought ALDX between November 3, 2023 and March 16, 2026 may be eligible to participate in the class action before the May 29 deadline. Article Title
• Neutral Sentiment: Bronstein, Gewirtz & Grossman said a class action lawsuit has already been filed against Aldeyra and certain officers, alleging violations of federal securities laws and seeking damages for shareholders. Article Title
• Neutral Sentiment: Investors are also being urged by firms such as SueWallSt and the Schall Law Firm to review alleged shortcomings in Aldeyra’s disclosures, which keeps litigation risk in focus for the stock. Article Title

Wall Street Analyst Weigh In

ALDX has been the topic of several research reports. Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. HC Wainwright reissued a “neutral” rating and set a $2.00 price target (down from $10.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, March 18th. BTIG Research reissued a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, March 17th. Finally, Wall Street Zen downgraded shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Aldeyra Therapeutics presently has an average rating of “Hold” and an average price target of $5.50.

Aldeyra Therapeutics Price Performance

The firm’s 50 day moving average is $1.84 and its 200 day moving average is $3.91. The company has a market capitalization of $93.50 million, a PE ratio of -3.37 and a beta of 1.16.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.07. As a group, analysts predict that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current fiscal year.

Insider Activity at Aldeyra Therapeutics

In other news, Director Richard Douglas bought 70,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were bought at an average cost of $1.40 per share, with a total value of $98,000.00. Following the completion of the purchase, the director directly owned 195,000 shares in the company, valued at $273,000. This represents a 56.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 9.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its position in Aldeyra Therapeutics by 146.6% during the 1st quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock valued at $1,459,000 after purchasing an additional 513,187 shares during the period. Dimensional Fund Advisors LP increased its position in Aldeyra Therapeutics by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 624,170 shares of the biotechnology company’s stock valued at $1,055,000 after purchasing an additional 11,912 shares during the period. Bank of New York Mellon Corp increased its position in Aldeyra Therapeutics by 18.1% during the 1st quarter. Bank of New York Mellon Corp now owns 136,746 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 20,980 shares during the period. Chicago Partners Investment Group LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter valued at $33,000. Finally, Abel Hall LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter valued at $26,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.